Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
Identifieur interne : 002D09 ( PubMed/Curation ); précédent : 002D08; suivant : 002D10Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
Auteurs : Ursula J. Buchholz [États-Unis] ; Alexander Bukreyev ; Lijuan Yang ; Elaine W. Lamirande ; Brian R. Murphy ; Kanta Subbarao ; Peter L. CollinsSource :
- Proceedings of the National Academy of Sciences of the United States of America [ 0027-8424 ] ; 2004.
Descripteurs français
- KwdFr :
- ADN recombiné (génétique), Administration par voie nasale, Animaux, Anticorps antiviraux (immunologie), Appareil respiratoire (immunologie), Appareil respiratoire (virologie), Cellules Vero, Cricetinae, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (génétique), Glycoprotéines membranaires (immunologie), Lignée cellulaire, Protéines de l'enveloppe virale (génétique), Protéines de l'enveloppe virale (immunologie), Protéines de la matrice virale (génétique), Protéines de la matrice virale (immunologie), Réplication virale (physiologie), Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (virologie), Tests de neutralisation, Vaccination, Vaccins antiviraux (administration et posologie), Vaccins antiviraux (génétique), Vaccins antiviraux (immunologie), Vecteurs génétiques (génétique), Virus du SRAS (), Virus du SRAS (croissance et développement), Virus du SRAS (génétique), Virus du SRAS (immunologie), Virus parainfluenza humain de type 3 (génétique).
- MESH :
- administration et posologie : Vaccins antiviraux.
- croissance et développement : Virus du SRAS.
- génétique : ADN recombiné, Glycoprotéines membranaires, Protéines de l'enveloppe virale, Protéines de la matrice virale, Vaccins antiviraux, Vecteurs génétiques, Virus du SRAS, Virus parainfluenza humain de type 3.
- immunologie : Anticorps antiviraux, Appareil respiratoire, Glycoprotéines membranaires, Protéines de l'enveloppe virale, Protéines de la matrice virale, Syndrome respiratoire aigu sévère, Vaccins antiviraux, Virus du SRAS.
- physiologie : Réplication virale.
- virologie : Appareil respiratoire, Syndrome respiratoire aigu sévère.
- Administration par voie nasale, Animaux, Cellules Vero, Cricetinae, Glycoprotéine de spicule des coronavirus, Lignée cellulaire, Syndrome respiratoire aigu sévère, Tests de neutralisation, Vaccination, Virus du SRAS.
English descriptors
- KwdEn :
- Administration, Intranasal, Animals, Antibodies, Viral (immunology), Cell Line, Chlorocebus aethiops, Cricetinae, DNA, Recombinant (genetics), Genetic Vectors (genetics), Membrane Glycoproteins (genetics), Membrane Glycoproteins (immunology), Neutralization Tests, Parainfluenza Virus 3, Human (genetics), Respiratory System (immunology), Respiratory System (virology), SARS Virus (chemistry), SARS Virus (genetics), SARS Virus (growth & development), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (virology), Spike Glycoprotein, Coronavirus, Vaccination, Vero Cells, Viral Envelope Proteins (genetics), Viral Envelope Proteins (immunology), Viral Matrix Proteins (genetics), Viral Matrix Proteins (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (genetics), Viral Vaccines (immunology), Virus Replication (physiology).
- MESH :
- chemical , administration & dosage : Viral Vaccines.
- chemical , genetics : DNA, Recombinant, Membrane Glycoproteins, Viral Envelope Proteins, Viral Matrix Proteins, Viral Vaccines.
- chemical , immunology : Antibodies, Viral, Membrane Glycoproteins, Viral Envelope Proteins, Viral Matrix Proteins, Viral Vaccines.
- chemistry : SARS Virus.
- genetics : Genetic Vectors, Parainfluenza Virus 3, Human, SARS Virus.
- growth & development : SARS Virus.
- immunology : Respiratory System, SARS Virus, Severe Acute Respiratory Syndrome.
- physiology : Virus Replication.
- prevention & control : Severe Acute Respiratory Syndrome.
- virology : Respiratory System, Severe Acute Respiratory Syndrome.
- Administration, Intranasal, Animals, Cell Line, Chlorocebus aethiops, Cricetinae, Neutralization Tests, Spike Glycoprotein, Coronavirus, Vaccination, Vero Cells.
Abstract
We investigated the contributions of the structural proteins of severe acute respiratory syndrome (SARS) coronavirus (CoV) to protective immunity by expressing them individually and in combinations from a recombinant parainfluenza virus (PIV) type 3 vector called BHPIV3. This vector provided direct immunization of the respiratory tract, the major site of SARS transmission, replication, and disease. The BHPIV3/SARS recombinants were evaluated for immunogenicity and protective efficacy in hamsters, which support a high level of pulmonary SARS-CoV replication. A single intranasal administration of BHPIV3 expressing the SARS-CoV spike protein (S) induced a high titer of SARS-CoV-neutralizing serum antibodies, only 2-fold less than that induced by SARS-CoV infection. The expression of S with the two other putative virion envelope proteins, the matrix M and small envelope E proteins, did not augment the neutralizing antibody response. In absence of S, expression of M and E or the nucleocapsid protein N did not induce a detectable serum SARS-CoV-neutralizing antibody response. Immunization with BHPIV3 expressing S provided complete protection against SARS-CoV challenge in the lower respiratory tract and partial protection in the upper respiratory tract. This was augmented slightly by coexpression with M and E. Expression of M, E, or N in the absence of S did not confer detectable protection. These results identify S among the structural proteins as the only significant SARS-CoV neutralization antigen and protective antigen and show that a single mucosal immunization is highly protective in an experimental animal that supports efficient replication of SARS-CoV.
DOI: 10.1073/pnas.0403492101
PubMed: 15210961
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002D09
Links to Exploration step
pubmed:15210961Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.</title><author><name sortKey="Buchholz, Ursula J" sort="Buchholz, Ursula J" uniqKey="Buchholz U" first="Ursula J" last="Buchholz">Ursula J. Buchholz</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-8007, USA. ubuchholz@niaid.nih.gov</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-8007</wicri:regionArea></affiliation></author><author><name sortKey="Bukreyev, Alexander" sort="Bukreyev, Alexander" uniqKey="Bukreyev A" first="Alexander" last="Bukreyev">Alexander Bukreyev</name></author><author><name sortKey="Yang, Lijuan" sort="Yang, Lijuan" uniqKey="Yang L" first="Lijuan" last="Yang">Lijuan Yang</name></author><author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W" last="Lamirande">Elaine W. Lamirande</name></author><author><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R" last="Murphy">Brian R. Murphy</name></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name></author><author><name sortKey="Collins, Peter L" sort="Collins, Peter L" uniqKey="Collins P" first="Peter L" last="Collins">Peter L. Collins</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15210961</idno><idno type="pmid">15210961</idno><idno type="doi">10.1073/pnas.0403492101</idno><idno type="wicri:Area/PubMed/Corpus">002D09</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002D09</idno><idno type="wicri:Area/PubMed/Curation">002D09</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002D09</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.</title><author><name sortKey="Buchholz, Ursula J" sort="Buchholz, Ursula J" uniqKey="Buchholz U" first="Ursula J" last="Buchholz">Ursula J. Buchholz</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-8007, USA. ubuchholz@niaid.nih.gov</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-8007</wicri:regionArea></affiliation></author><author><name sortKey="Bukreyev, Alexander" sort="Bukreyev, Alexander" uniqKey="Bukreyev A" first="Alexander" last="Bukreyev">Alexander Bukreyev</name></author><author><name sortKey="Yang, Lijuan" sort="Yang, Lijuan" uniqKey="Yang L" first="Lijuan" last="Yang">Lijuan Yang</name></author><author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W" last="Lamirande">Elaine W. Lamirande</name></author><author><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R" last="Murphy">Brian R. Murphy</name></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name></author><author><name sortKey="Collins, Peter L" sort="Collins, Peter L" uniqKey="Collins P" first="Peter L" last="Collins">Peter L. Collins</name></author></analytic><series><title level="j">Proceedings of the National Academy of Sciences of the United States of America</title><idno type="ISSN">0027-8424</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term><term>Animals</term><term>Antibodies, Viral (immunology)</term><term>Cell Line</term><term>Chlorocebus aethiops</term><term>Cricetinae</term><term>DNA, Recombinant (genetics)</term><term>Genetic Vectors (genetics)</term><term>Membrane Glycoproteins (genetics)</term><term>Membrane Glycoproteins (immunology)</term><term>Neutralization Tests</term><term>Parainfluenza Virus 3, Human (genetics)</term><term>Respiratory System (immunology)</term><term>Respiratory System (virology)</term><term>SARS Virus (chemistry)</term><term>SARS Virus (genetics)</term><term>SARS Virus (growth & development)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccination</term><term>Vero Cells</term><term>Viral Envelope Proteins (genetics)</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Matrix Proteins (genetics)</term><term>Viral Matrix Proteins (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (genetics)</term><term>Viral Vaccines (immunology)</term><term>Virus Replication (physiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ADN recombiné (génétique)</term><term>Administration par voie nasale</term><term>Animaux</term><term>Anticorps antiviraux (immunologie)</term><term>Appareil respiratoire (immunologie)</term><term>Appareil respiratoire (virologie)</term><term>Cellules Vero</term><term>Cricetinae</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires (génétique)</term><term>Glycoprotéines membranaires (immunologie)</term><term>Lignée cellulaire</term><term>Protéines de l'enveloppe virale (génétique)</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Protéines de la matrice virale (génétique)</term><term>Protéines de la matrice virale (immunologie)</term><term>Réplication virale (physiologie)</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Tests de neutralisation</term><term>Vaccination</term><term>Vaccins antiviraux (administration et posologie)</term><term>Vaccins antiviraux (génétique)</term><term>Vaccins antiviraux (immunologie)</term><term>Vecteurs génétiques (génétique)</term><term>Virus du SRAS ()</term><term>Virus du SRAS (croissance et développement)</term><term>Virus du SRAS (génétique)</term><term>Virus du SRAS (immunologie)</term><term>Virus parainfluenza humain de type 3 (génétique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>DNA, Recombinant</term><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term><term>Viral Matrix Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term><term>Viral Matrix Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="croissance et développement" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Genetic Vectors</term><term>Parainfluenza Virus 3, Human</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ADN recombiné</term><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Protéines de la matrice virale</term><term>Vaccins antiviraux</term><term>Vecteurs génétiques</term><term>Virus du SRAS</term><term>Virus parainfluenza humain de type 3</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Appareil respiratoire</term><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Protéines de la matrice virale</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Respiratory System</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Réplication virale</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Appareil respiratoire</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Respiratory System</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term><term>Animals</term><term>Cell Line</term><term>Chlorocebus aethiops</term><term>Cricetinae</term><term>Neutralization Tests</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccination</term><term>Vero Cells</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie nasale</term><term>Animaux</term><term>Cellules Vero</term><term>Cricetinae</term><term>Glycoprotéine de spicule des coronavirus</term><term>Lignée cellulaire</term><term>Syndrome respiratoire aigu sévère</term><term>Tests de neutralisation</term><term>Vaccination</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We investigated the contributions of the structural proteins of severe acute respiratory syndrome (SARS) coronavirus (CoV) to protective immunity by expressing them individually and in combinations from a recombinant parainfluenza virus (PIV) type 3 vector called BHPIV3. This vector provided direct immunization of the respiratory tract, the major site of SARS transmission, replication, and disease. The BHPIV3/SARS recombinants were evaluated for immunogenicity and protective efficacy in hamsters, which support a high level of pulmonary SARS-CoV replication. A single intranasal administration of BHPIV3 expressing the SARS-CoV spike protein (S) induced a high titer of SARS-CoV-neutralizing serum antibodies, only 2-fold less than that induced by SARS-CoV infection. The expression of S with the two other putative virion envelope proteins, the matrix M and small envelope E proteins, did not augment the neutralizing antibody response. In absence of S, expression of M and E or the nucleocapsid protein N did not induce a detectable serum SARS-CoV-neutralizing antibody response. Immunization with BHPIV3 expressing S provided complete protection against SARS-CoV challenge in the lower respiratory tract and partial protection in the upper respiratory tract. This was augmented slightly by coexpression with M and E. Expression of M, E, or N in the absence of S did not confer detectable protection. These results identify S among the structural proteins as the only significant SARS-CoV neutralization antigen and protective antigen and show that a single mucosal immunization is highly protective in an experimental animal that supports efficient replication of SARS-CoV.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15210961</PMID><DateCompleted><Year>2004</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>101</Volume><Issue>26</Issue><PubDate><Year>2004</Year><Month>Jun</Month><Day>29</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation></Journal><ArticleTitle>Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.</ArticleTitle><Pagination><MedlinePgn>9804-9</MedlinePgn></Pagination><Abstract><AbstractText>We investigated the contributions of the structural proteins of severe acute respiratory syndrome (SARS) coronavirus (CoV) to protective immunity by expressing them individually and in combinations from a recombinant parainfluenza virus (PIV) type 3 vector called BHPIV3. This vector provided direct immunization of the respiratory tract, the major site of SARS transmission, replication, and disease. The BHPIV3/SARS recombinants were evaluated for immunogenicity and protective efficacy in hamsters, which support a high level of pulmonary SARS-CoV replication. A single intranasal administration of BHPIV3 expressing the SARS-CoV spike protein (S) induced a high titer of SARS-CoV-neutralizing serum antibodies, only 2-fold less than that induced by SARS-CoV infection. The expression of S with the two other putative virion envelope proteins, the matrix M and small envelope E proteins, did not augment the neutralizing antibody response. In absence of S, expression of M and E or the nucleocapsid protein N did not induce a detectable serum SARS-CoV-neutralizing antibody response. Immunization with BHPIV3 expressing S provided complete protection against SARS-CoV challenge in the lower respiratory tract and partial protection in the upper respiratory tract. This was augmented slightly by coexpression with M and E. Expression of M, E, or N in the absence of S did not confer detectable protection. These results identify S among the structural proteins as the only significant SARS-CoV neutralization antigen and protective antigen and show that a single mucosal immunization is highly protective in an experimental animal that supports efficient replication of SARS-CoV.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buchholz</LastName><ForeName>Ursula J</ForeName><Initials>UJ</Initials><AffiliationInfo><Affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-8007, USA. ubuchholz@niaid.nih.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bukreyev</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Lijuan</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Lamirande</LastName><ForeName>Elaine W</ForeName><Initials>EW</Initials></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Author><Author ValidYN="Y"><LastName>Subbarao</LastName><ForeName>Kanta</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Peter L</ForeName><Initials>PL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2004</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004274">DNA, Recombinant</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014763">Viral Matrix Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004274" MajorTopicYN="N">DNA, Recombinant</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010224" MajorTopicYN="N">Parainfluenza Virus 3, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012137" MajorTopicYN="N">Respiratory System</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth & development</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014763" MajorTopicYN="N">Viral Matrix Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>6</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>8</Month><Day>13</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>6</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15210961</ArticleId><ArticleId IdType="doi">10.1073/pnas.0403492101</ArticleId><ArticleId IdType="pii">0403492101</ArticleId><ArticleId IdType="pmc">PMC470755</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vaccine. 2000 Jan 31;18(14):1359-66</Citation><ArticleIdList><ArticleId IdType="pubmed">10618533</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1999 Jan;73(1):251-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9847328</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Comp Immunol. 2000 Mar-Apr;24(2-3):187-200</Citation><ArticleIdList><ArticleId IdType="pubmed">10717287</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2000 Sep;74(17):8127-34</Citation><ArticleIdList><ArticleId IdType="pubmed">10933723</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2000 Oct;74(19):8922-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10982335</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2001 May 18;276(20):17515-23</Citation><ArticleIdList><ArticleId IdType="pubmed">11278557</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11413487</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2002 Feb;76(3):1089-99</Citation><ArticleIdList><ArticleId IdType="pubmed">11773385</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2002 Sep;76(18):9284-97</Citation><ArticleIdList><ArticleId IdType="pubmed">12186912</ArticleId></ArticleIdList></Reference><Reference><Citation>Wkly Epidemiol Rec. 2003 Mar 21;78(12):81-3</Citation><ArticleIdList><ArticleId IdType="pubmed">12701272</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2003 Jul 20;312(1):25-34</Citation><ArticleIdList><ArticleId IdType="pubmed">12890618</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2003 Dec 15;37(12):1668-77</Citation><ArticleIdList><ArticleId IdType="pubmed">14689350</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId></ArticleIdList></Reference><Reference><Citation>Comp Immunol Microbiol Infect Dis. 1981;4(2):175-89</Citation><ArticleIdList><ArticleId IdType="pubmed">6754243</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 1987 Oct 26;15(20):8125-48</Citation><ArticleIdList><ArticleId IdType="pubmed">3313277</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1990 Mar;64(3):1407-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2154621</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1991 Mar;181(1):327-35</Citation><ArticleIdList><ArticleId IdType="pubmed">1847259</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1991 Mar;65(3):1634-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1995956</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1993 Feb;67(2):1044-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8419638</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1995 Apr 14;270(15):8815-21</Citation><ArticleIdList><ArticleId IdType="pubmed">7721788</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1995 May;171(5):1107-14</Citation><ArticleIdList><ArticleId IdType="pubmed">7751684</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1995 Oct;131(2):339-49</Citation><ArticleIdList><ArticleId IdType="pubmed">7593163</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1996 Apr 15;15(8):2020-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8617249</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1996 Apr 1;218(1):52-60</Citation><ArticleIdList><ArticleId IdType="pubmed">8615041</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1998 Feb;72(2):891-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9444980</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1998 May 18;141(4):929-42</Citation><ArticleIdList><ArticleId IdType="pubmed">9585412</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2000 Feb;74(3):1566-71</Citation><ArticleIdList><ArticleId IdType="pubmed">10627571</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D09 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002D09 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:15210961
|texte= Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:15210961" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |